Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 1/20 | 0.37 |
| ▸ | MAP2K1 | Q02750 | 13/20 | 0.36 |
| ▸ | MAP2K2 | P36507 | 7/20 | 0.36 |
| ▸ | KIT | P10721 | 1/20 | 0.35 |
| ▸ | BRAF | P15056 | 4/20 | 0.34 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.33 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.33 |
| ▸ | PRKAG1 | P54619 | 1/20 | 0.33 |
| ▸ | ADCK1 | Q86TW2 | 1/20 | 0.33 |
| ▸ | PRKAG2 | Q9UGJ0 | 1/20 | 0.33 |
| ▸ | AURKA | O14965 | 1/20 | 0.33 |
| ▸ | TNFRSF1A | P19438 | 1/20 | 0.33 |
| ▸ | KDR | P35968 | 1/20 | 0.33 |
| ▸ | MAP3K9 | P80192 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20034585 | 0.88 | MRGPRX1 (0.39) | KITBRAF | |
| SCHEMBL1992129 | 0.83 | IDO1 (0.38) | IDO1MAP2K1MAP2K2KITBRAF | |
| SCHEMBL15129483 | 0.81 | BRAF (0.35) | MAP2K1MAP2K2KITBRAF | |
| SCHEMBL15129534 | 0.80 | MAP2K1 (0.36) | IDO1MAP2K1MAP2K2KITBRAF | |
| SCHEMBL15129651 | 0.80 | MAP2K1 (0.36) | IDO1MAP2K1MAP2K2CHEK1MAPK10 | |
| SCHEMBL391574 | 0.80 | MAP2K1 (0.53) | MAP2K1MAP2K2BRAFCA2 | |
| SCHEMBL1343990 | 0.80 | MAP2K1 (0.46) | MAP2K1MAP2K2BRAF | |
| SCHEMBL15129461 | 0.79 | MAP2K1 (0.40) | IDO1MAP2K1MAP2K2BRAFCHEK1 | |
| SCHEMBL1343469 | 0.79 | MAP2K1 (0.41) | IDO1MAP2K1MAP2K2KITBRAF | |
| SCHEMBL1341284 | 0.79 | IDO1 (0.38) | IDO1MAP2K1MAP2K2KITBRAF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9937158-B2 | Benzoheterocyclic compounds and use thereof | SHANGHAI KECHOW PHARMA, INC. (CN) | 2018-04-10 | — | — | US | claimed |
| EP-2804855-B1 | BENZOHETEROCYCLIC COMPOUNDS AND USE THEREOF | SHANGHAI KECHOW PHARMA INC (CN) | 2017-09-20 | — | — | EP | claimed |
| US-20160235721-A1 | BENZOHETEROCYCLIC COMPOUNDS AND USE THEREOF | TIANJIN BINJIANG PHARMA, INC. (CN) | 2016-08-18 | — | — | US | claimed |
| US-9290468-B2 | Benzoheterocyclic compounds and use thereof | SHANGHAI KECHOW PHARMA, INC. (CN) | 2016-03-22 | — | — | US | claimed |
| US-20140371278-A1 | BENZOHETEROCYCLIC COMPOUNDS AND USE THEREOF | TIANJIN BINJIANG PHARMA, INC. (CN) | 2014-12-18 | — | — | US | claimed |
| EP-2804855-A1 | BENZOHETEROCYCLIC COMPOUNDS AND USE THEREOF | Tianjin Binjiang Pharma, Inc. (CN) | 2014-11-26 | — | — | EP | claimed |
| WO-2013107283-A1 | BENZOHETEROCYCLIC COMPOUNDS AND USE THEREOF | TIANJIN BINJIANG PHARMA, INC. (CN) | 2013-07-25 | — | — | WO | claimed |
| US-9937158-B2 | Benzoheterocyclic compounds and use thereof | SHANGHAI KECHOW PHARMA, INC. (CN) | 2018-04-10 | — | — | US | disclosed |
| US-9937158-B2 | Benzoheterocyclic compounds and use thereof | SHANGHAI KECHOW PHARMA, INC. (CN) | 2018-04-10 | — | — | US | disclosed |
| EP-2804855-B1 | BENZOHETEROCYCLIC COMPOUNDS AND USE THEREOF | SHANGHAI KECHOW PHARMA INC (CN) | 2017-09-20 | — | — | EP | disclosed |
| EP-2804855-B1 | BENZOHETEROCYCLIC COMPOUNDS AND USE THEREOF | SHANGHAI KECHOW PHARMA INC (CN) | 2017-09-20 | — | — | EP | disclosed |
| US-20160235721-A1 | BENZOHETEROCYCLIC COMPOUNDS AND USE THEREOF | TIANJIN BINJIANG PHARMA, INC. (CN) | 2016-08-18 | — | — | US | disclosed |
| US-20160235721-A1 | BENZOHETEROCYCLIC COMPOUNDS AND USE THEREOF | TIANJIN BINJIANG PHARMA, INC. (CN) | 2016-08-18 | — | — | US | disclosed |
| US-9290468-B2 | Benzoheterocyclic compounds and use thereof | SHANGHAI KECHOW PHARMA, INC. (CN) | 2016-03-22 | — | — | US | disclosed |
| US-9290468-B2 | Benzoheterocyclic compounds and use thereof | SHANGHAI KECHOW PHARMA, INC. (CN) | 2016-03-22 | — | — | US | disclosed |
| US-20140371278-A1 | BENZOHETEROCYCLIC COMPOUNDS AND USE THEREOF | TIANJIN BINJIANG PHARMA, INC. (CN) | 2014-12-18 | — | — | US | disclosed |
| US-20140371278-A1 | BENZOHETEROCYCLIC COMPOUNDS AND USE THEREOF | TIANJIN BINJIANG PHARMA, INC. (CN) | 2014-12-18 | — | — | US | disclosed |
| WO-2013107283-A1 | BENZOHETEROCYCLIC COMPOUNDS AND USE THEREOF | TIANJIN BINJIANG PHARMA, INC. (CN) | 2013-07-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140371278-A1 | BENZOHETEROCYCLIC COMPOUNDS AND USE THEREOF | CDK2, CDK1, MAP3K1 | IDO1 2570/4885MAP2K1 436/4885MAP2K2 247/4885 |
| US-20160235721-A1 | BENZOHETEROCYCLIC COMPOUNDS AND USE THEREOF | CDK2, MAPK1, BDKRB1 | IDO1 2394/4885MAP2K1 393/4885MAP2K2 233/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.